The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Baeuerle Patrick since 2019.
This trader's CIK number is 1362054.
At the time of last reporting, Baeuerle Patrick was the See Remarks of Cullinan Oncology, Inc.. (stock ticker symbol CGEM).
Also see all insider trading activities at Cullinan Oncology, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | CGEM | 0 | $0 | 22,000 | $609,950 | 22,000 | $94,600 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2019 | TCRR | 0 | $0 | 116,929 | $1,796,417 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2019 | HARP | 0 | $0 | 87,379 | $1,479,151 | 0 | $0 |
1. Cullinan Oncology, Inc. (CGEM)
2. Tcr2 Therapeutics Inc. (TCRR)
3. Harpoon Therapeutics, Inc. (HARP)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-09-08 | CGEM | Sale | 11,000 | 28.45 | 312,950 |
| 2021-09-08 | CGEM | Option Ex | 11,000 | 4.30 | 47,300 |
| 2021-08-10 | CGEM | Sale | 11,000 | 27.00 | 297,000 |
| 2021-08-10 | CGEM | Option Ex | 11,000 | 4.30 | 47,300 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-12-20 | TCRR | Sale | 32,022 | 15.16 | 485,453 |
| 2019-12-23 | TCRR | Sale | 84,907 | 15.44 | 1,310,964 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-12-27 | HARP | Sale | 87,379 | 16.93 | 1,479,151 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Baeuerle Patrick (See Remarks of Cullinan Oncology, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.